Basics Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. IPO Date: April 14, 2004 Sector: Healthcare Industry: Pharma Market Cap: $7.57B Activated in VL: True Average Daily Range Avg Daily Range: $0.27 | 2.79% Avg Daily Range (30 D): $1.31 | 1.82% Avg Daily Range (90 D): $1.98 | 2.59% Institutional Daily Volume Avg Daily Volume: .48M Avg Daily Volume (30 D): .8M Avg Daily Volume (90 D): 1.23M Trade Size Avg Trade Size (Sh.): 102 Avg Trade Size (Sh.) (30 D): 40 Avg Trade Size (Sh.) (90 D): 47 Institutional Trades Total Inst.Trades: 4,272 Avg Inst. Trade: $2.7M Avg Inst. Trade (30 D): $9.18M Avg Inst. Trade (90 D): $6.64M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.7M Avg Closing Trade (30 D): $20.24M Avg Closing Trade (90 D): $16.26M Avg Closing Volume: 140.56K     News May 8, 2025 @ 5:00 PM High- and Low-Grade Serous Ovarian Cancer Market i... Source: Delveinsight Dec 11, 2024 @ 6:00 PM Alcohol Use Disorder Market Set for Remarkable Gro... Source: Delveinsight Sep 19, 2024 @ 7:36 PM Corcept Moves 6.5% Higher: Will This Strength Last... Source: Zacks Sep 3, 2024 @ 8:29 PM Corcept Shares Rise More Than 45% in Six Months: H... Source: Zacks Aug 6, 2024 @ 10:20 AM Should You Invest in the First Trust NYSE Arca Bio... Source: Zacks Investment Research Financials   TTM Q1 2025 Q4 2024 Basic EPS $1.27 $.19 $.29 Diluted EPS $1.15 $.17 $.25 Revenue $ 685.45M $ 157.21M $ 181.89M Gross Profit $ 674.7M $ 154.81M $ 178.93M Net Income / Loss $ 133.99M $ 20.55M $ 30.75M Operating Income / Loss $ 110.87M $ 3.42M $ 25.26M Cost of Revenue $ 10.75M $ 2.4M $ 2.96M Net Cash Flow $ -59.93M $ -37.85M $ -9.62M PE Ratio 0.00